VIR Stock — Vir Biotechnology Inc.: Cash, EV, Pipeline

Share price

$10.60

Market cap

$1,793.7M

Cash

$528.6M

Enterprise value

$1,265.1M

Balance sheet

Cash	$528.6M
Debt	$0.0M
Net cash	$528.6M
Enterprise value	$1,265.1M
Basic shares	169.2M shares
Fully diluted shares	186.6M shares
Fully diluted market cap	$1,978.1M
Cash per share	$3.12

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading VIR daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Dec 13, 2026 - Jan 24, 2027	Tobevibart	Phase 2	Viral Hepatitis	—
Jan 12 - Feb 23	Tobevibart	Phase 3	Viral Hepatitis	—
Feb 11 - Mar 25	Tobevibart	Phase 3	Viral Hepatitis	—
May 13 - Jun 24	VIR-5818	Phase 1/2	Locally Advanced or Metastatic HER2-Expressing Cancers	—
Sep 12 - Oct 24	VIR-5525	Phase 1	Solid Tumor Malignancies; EGFR Positive Solid Tumors; EGFR	—
Dec 13, 2031 - Jan 24, 2032	VIR-2218	Phase 2	Hepatitis D, Chronic	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

elebsiran/tobevibart

Phase 3 · Active Modality: siRNA (elebsiran) plus monoclonal antibody (tobevibart) combination

Target Hepatitis B/D virus

Partnerships Norgine (exclusive license for commercial and certain development rights in Europe, Australia and New Zealand; contributes ~25% of ECLIPSE external costs from January 1, 2026); Alnylam (worldwide license to siRNA directed to HBV/HDV, including elebsiran)

Indications

Chronic hepatitis delta (Phase 3)

Status note Investigational elebsiran/tobevibart combination being evaluated in the ECLIPSE registrational program (ECLIPSE 1, 2 and 3) for chronic hepatitis delta; Vir Bio retains commercial rights in the U.S. and all other markets outside the Norgine Territory and China/Taiwan.

VIR-5500

Phase 1 · Active Modality: dual-masked CD3 T-cell engager (PRO-XTEN)

Target PSMA

Partnerships Astellas (global strategic collaboration to co-develop and co-commercialize; closed April 15, 2026 with $240.0 million upfront); Sanofi (exclusive worldwide PRO-XTEN masking license)

Indications

Prostate cancer (Phase 1)

Status note PRO-XTEN dual-masked CD3 TCE in Phase 1 development; global clinical development costs shared 40% Vir Bio / 60% Astellas, U.S. profits and losses shared equally.

VIR-5525

Phase 1 · Active Modality: dual-masked T-cell engager (PRO-XTEN)

Target EGFR

Partnerships Sanofi (in-licensed dual-masked TCE; exclusive worldwide PRO-XTEN masking license)

Indications

Oncology (solid tumors) (Phase 1)

Status note First patient dosed in a Phase 1 study in July 2025; in-licensed from Sanofi/Amunix with the PRO-XTEN masking platform.

Per-asset detail extracted from the 10-Q filed 2026-08-05. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	Tobevibart
Lead indication	Viral Hepatitis
Lead phase	Phase 3
Active trials	6

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07128550	Phase 3	Active, not recruiting	Sponsor	Vir Biotechnology, Inc.	—	Viral Hepatitis	—
NCT06903338	Phase 3	Active, not recruiting	Sponsor	Vir Biotechnology, Inc.	—	Viral Hepatitis	—
NCT07142811	Phase 2	Active, not recruiting	Sponsor	Vir Biotechnology, Inc.	—	Viral Hepatitis	—
NCT05461170	Phase 2	Active, not recruiting	Sponsor	Vir Biotechnology, Inc.	—	Hepatitis D, Chronic	—
NCT05356741	Phase 1/2	Recruiting	Sponsor	Vir Biotechnology, Inc.	MRK	Locally Advanced or Metastatic HER2-Expressing Cancers	—
NCT06960395	Phase 1	Recruiting	Sponsor	Vir Biotechnology, Inc.	—	Solid Tumor Malignancies; EGFR Positive Solid Tumors; EGFR	—

Sponsor-matched active trials from ClinicalTrials.gov (6 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 6 active trials for Vir Biotechnology, Inc. on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
ADAR1 Capital Management	2,456,677	-288,037	1.18%	2026-08-14
Ikarian Capital	0	-293,258	0.00%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

VIR — Vir Biotechnology Inc.

Balance sheet

Price history

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Institutional holders